Position：Home >
Concanavalin A (Con A) injection via tail vein to induce an autoimmune hepatitis model
Concanavalin A (Con A) injection via tail vein to induce an autoimmune hepatitis model
Background
Concanavalin A (Con A)-induced liver injury model is similar to liver injury caused by autoimmune liver disease and viral hepatitis. Its pathological changes and hepatocyte injury mechanisms are comparable to those of viral hepatitis, so it is regarded as a suitable model for studying human diseases such as viral hepatitis and autoimmune hepatitis.
Con A can activate and proliferate T cells, and induce increased expression of Th1 cytokines including IL‑2, TNF‑α and IFN‑γ. High levels of pro‑inflammatory factors lead to intrahepatic inflammation and hepatocyte apoptosis, even resulting in acute liver failure, accompanied by abnormal liver function indicators such as AST and ALP.
Materials and methods
Balb/c mice (male, 6–8 weeks old)
Modeling method: Establishment of an autoimmune hepatitis model in mice by tail vein injection of concanavalin A (Con A).
Positive drug: prednisolone
Evaluation indicators: HE staining, TUNEL staining, serum biochemical assay
Modeling method: Establishment of an autoimmune hepatitis model in mice by tail vein injection of concanavalin A (Con A).
Positive drug: prednisolone
Evaluation indicators: HE staining, TUNEL staining, serum biochemical assay
Test and verify
HE staining of liver tissue
TUNEL staining of liver tissue
Serum biochemical assay
